Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-Risk Patients With Metastatic Renal Cell Carcinoma.

Trial Profile

Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-Risk Patients With Metastatic Renal Cell Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 02 Apr 2015 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov.
    • 29 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as per ClinicalTrials.gov record.
    • 29 Jan 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top